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Abstract: Severe exacerbations of COPD, ie, those leading to hospitalization, have profound 
clinical implications for patients and significant economic consequences for society. The 
prevalence and burden of severe COPD exacerbations remain high, despite recognition of the 
importance of exacerbation prevention and the availability of new treatment options. Severe 
COPD exacerbations are associated with high mortality, have negative impact on quality of 
life, are linked to cardiovascular complications, and are a significant burden on the health-care 
system. This review identified risk factors that contribute to the development of severe exacer-
bations, treatment options (bronchodilators, antibiotics, corticosteroids [CSs], oxygen therapy, 
and ventilator support) to manage severe exacerbations, and strategies to prevent readmission 
to hospital. Risk factors that are amenable to change have been highlighted. A number of bron-
chodilators have demonstrated successful reduction in risk of severe exacerbations, including 
long-acting muscarinic antagonist or long-acting β
2
-agonist mono- or combination therapies, in 
addition to vaccination, mucolytic and antibiotic therapy, and nonpharmacological interventions, 
such as pulmonary rehabilitation. Recognition of the importance of severe exacerbations is an 
essential step in improving outcomes for patients with COPD. Evidence-based approaches to 
prevent and manage severe exacerbations should be implemented as part of targeted strategies 
for disease management.
Keywords: severe COPD exacerbations, hospitalization, prevention, treatment, bronchodilators, 
long-acting muscarinic antagonist
Introduction
Exacerbations of COPD are important events in the course of the disease that have 
profound impact on patients’ health status, functional capacity, and lung function.1,2 
The severity of exacerbations varies, and the clinical definition of a severe exacerba-
tion is not always uniform; for practical reasons, clinical trials and epidemiological 
studies normally define severe exacerbations as those resulting in hospitalization.3 
Severe exacerbations have a particularly significant clinical and socioeconomic impact. 
A recent database review of .73,000 patients found that fewer than half of patients 
hospitalized for an exacerbation survived for a further 5 years.4 Patients who survive 
severe exacerbations are likely to experience significantly impaired quality of life 
(QoL), are at increased risk of further exacerbations,5,6 and represent a major contributor 
to the overall health-care costs associated with COPD.7,8 Therefore, understanding the 
factors that lead to an exacerbation being so severe that treatment in hospital is needed, 
and optimization of patient management to reduce the risk of severe exacerbations, 
are crucial therapeutic goals for patients with stable COPD.
Currently, the prevalence and burden of severe exacerbations remain high,9,10 
despite advances in COPD therapies and increased recognition of the importance 
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of preventing exacerbations. This manuscript reviews the 
risk factors, consequences, and treatment of severe COPD 
exacerbations, and highlights opportunities to improve the 
management and prevention of these serious events.
What constitutes a severe 
exacerbation?
An exacerbation is typically considered an acute episode 
characterized by worsening of the patient’s respiratory 
symptoms (ie, baseline dyspnea, cough, and/or sputum 
production) that is sufficient to require additional therapy.11,12 
The American Thoracic Society (ATS)/European Respira-
tory Society (ERS) guidelines classify any exacerbation that 
can be managed at home (mild or moderate) as level I, while 
severe exacerbations are stratified further as those requiring 
hospitalization (level II) and those leading to respiratory 
failure (level III).12 For the purposes of this review, severe 
exacerbations refers to exacerbations requiring hospitaliza-
tion, accepting that exacerbations requiring hospitalization 
may be quite varied in terms of the severity of respiratory 
symptoms and will also reflect the underlying severity of 
the patient’s lung impairment. In patients with very limited 
respiratory reserves, less severe exacerbation events may still 
require hospitalization for effective management. Additional 
factors that contribute to the decision to admit a patient to 
hospital include the presence of such comorbidities as heart 
failure, cardiac arrhythmia, or pneumonia, or the onset of 
other clinical signs, such as central cyanosis or peripheral 
edema.11,12 Patients may go into hospital as an acute emer-
gency admission or be admitted only after outpatient man-
agement of an exacerbation has failed to produce an adequate 
response. Psychosocial factors may also be involved: the 
patient’s ability to cope at home, which may be a product of 
their age, mental status, and the level of support they have 
available to them, is an important consideration in deciding 
whether they should be treated for an exacerbation as an inpa-
tient or outpatient.11–13 Finally, regional differences in local 
health-care practices and access to health-care services also 
influence the threshold that determines hospitalization for 
patients with COPD suffering an exacerbation of COPD.14
What are the likely clinical 
outcomes of severe COPD 
exacerbations?
Severe COPD exacerbations have short- and long-term clinical 
implications, including accelerated loss of lung function, 
increased mortality, decreased health status, cardiovas-
cular comorbidity, and increased health-care costs.7,15,16 
An exacerbation has a significant effect on clinical and patient-
centered outcomes, including obstruction, dyspnea, and exer-
cise capacity. Patients take a long time to recover from these 
effects, and may never return to their preexacerbation state.17
Impact on mortality
Hospitalization for COPD exacerbations is associated with 
a high mortality rate. In an EU COPD audit, 5% of patients 
admitted to hospital with a COPD exacerbation died while 
in hospital.10 Consistent with this finding, a recent database 
review of .73,000 patients with up to 17 years’ follow-up 
found that mortality peaked in the first week and remained 
high during the first 3 months following hospital admission.4 
Fewer than half of patients hospitalized for an exacerbation 
were still alive after 5 years’ follow-up in this study.4 This 
is consistent with previous reports of .50% mortality at 
5 years following hospitalization for acute exacerbations 
of COPD.18,19 Long-term posthospitalization mortality rates 
reported in the literature are quite variable: 12%–33% after 
1 year,18–22 26%–39% after 2 years,18,21,22 39%–49% after 
3 years,18,21,22 and 45%–47% after 4 years.18,22 It has been 
suggested that survival following hospitalization for COPD 
is improving.23 However, mortality associated with COPD 
may be underestimated, as it is often cited as a contribu-
tory, rather than underlying, cause of death, or omitted from 
death certificates altogether if death is primarily attributed to 
comorbid conditions.24 The contribution of nonhospitalized 
exacerbations to mortality rates (ie, unreported exacerbations 
that should have warranted hospital treatment) has not been 
well quantified.25 Mortality risk increases with each new exac-
erbation: there is a fivefold greater risk of mortality after the 
tenth hospitalization compared with the first (Figure 1).4
Identified risk factors for mortality associated with severe 
exacerbation include older age, male sex, prior hospitaliza-
tions, weight loss/low body-mass index, poor QoL, physi-
ological parameters (eg, partial pressure of carbon dioxide 
[PaCO
2
]), pulmonary hypertension, lung cancer, cardiovas-
cular comorbidity, and need for long-term oxygen therapy 
at discharge.4,6,9,18,19,22,26–28
Health-related quality of life
Health-related QoL deteriorates in patients experiencing 
exacerbations; the more frequent and severe the exacerbation, 
the more rapid and pronounced the decline.29–31 Severe exac-
erbations lead to impairment of the ability to perform usual 
activities and reduce work productivity. Activity limitation 
and reduced work productivity have been found to be strongly 
correlated with the total number of severe exacerbations in 
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the previous year.30 Assessment of health-related QoL varies 
considerably between studies, and some measures do not 
include all domains of health status (physiological function-
ing, symptoms, functional impairment, and QoL).32
Cardiovascular sequelae
Cardiovascular comorbidities are common in patients with 
COPD, and particularly in those patients with more severe 
airflow limitation. A review of studies of patients hospitalized 
for COPD exacerbations found that up to 55% of patients had 
a history of cardiovascular disease.33 Exacerbations of COPD 
have a profound effect on patients’ cardiovascular status,33–35 
and the increase in cardiac events after the first exacerbation 
is irrespective of the patient’s cardiac history.36 Markers of 
myocardial injury, including raised troponin, chest pain, and 
serial electrocardiogram changes, are commonly observed in 
patients admitted to hospital with exacerbations of COPD.33,34 
Levels of N-terminal pro–brain natriuretic peptide and cardiac 
troponin T are elevated during acute exacerbations of COPD 
and thought to be a predictor of mortality among patients 
admitted to hospital.37 Arterial stiffness also rises acutely 
during COPD exacerbations, particularly when associated 
with airway infection.35 These changes may also be associated 
with an acute increase in the risk of myocardial infarction 
(MI): a UK observational database study found a 2.3-fold 
increase in the risk of MI 1–5 days postexacerbation,38 while 
analysis from the UPLIFT® study showed 13-fold increased 
risk of MI in the 30 days postexacerbation compared with 
preexacerbation periods. A 17-fold increase in the occurrence 
of atrial fibrillation/flutter was also seen in the 30-day postex-
acerbation period.36
Increased prevalence of pulmonary embolism has also 
been reported in patients with COPD exacerbations. Two 
meta-analyses have reported an overall incidence of pulmo-
nary embolism of 16%39 and 20%,40 increasing to 25% in 
hospitalized patients, including those hospitalized specifi-
cally for a COPD exacerbation.40
What is the epidemiology and 
economic impact of severe 
exacerbations?
Rates of hospitalization for exacerbations of COPD vary 
in different countries, which may reflect differences in the 
organization of health-care systems. A large international 
survey of more than 4,000 patients with COPD sampled 
from 12 countries in Europe, the US, and Asia (Continuing 
to Confront COPD International Patient Survey) found that 
overall, 15% of patients had been hospitalized for an exacer-
bation in the previous 12 months, with rates ranging 5%–25% 
across individual countries (Figure 2).41 In another large 
multinational survey of more than 1,000 patients in Germany, 
France, Italy, Spain, the UK, and the US (PERCEIVE), 
21% of patients who reported a COPD exacerbation in the 
preceding year were hospitalized.42
Severe COPD exacerbations are estimated to account for 
less than 10% of exacerbations,43,44 but have a disproportion-
ate and significant socioeconomic impact, with hospitaliza-
tions estimated to account for approximately 60%–70% of 
health-care costs associated with COPD, depending on the 
region.8,45 Illustrative of the costs associated with COPD 
exacerbations, a recent health-economics analysis conducted 
in the US, based on a data set from 2006, identified a total 
of 1,254,703 hospitalizations for COPD exacerbations, 
with total inpatient costs of $11.9 billion over the year at 
a mean cost of $9,545 per hospitalized exacerbation.46 The 
substantial burden of severe COPD exacerbations is appar-
ent when considered in the context of overall health-care 
resource utilization. In the UK, acute exacerbations account 
for 115,000 hospital admissions per year, representing one 
of the most common reasons for emergency admission to 
hospital,47 while in Spain it is estimated that 1%–2% of all 
emergency-service visits and 10% of all medical admissions 
are attributable to COPD exacerbations.18
Despite trends toward an improvement in in-hospital mor-
tality rates and a reduction in average length of hospital stay 
in the US,9,48 there has been no significant improvement in 
other indicators, including the number of hospital discharges, 
Figure 1 Hazard function of successive hospitalized COPD exacerbations (per 
10,000 per day) for a cohort of 73,106 patients from the time of their first ever 
hospitalization for a COPD exacerbation over the follow-up period, with the time 
between successive exacerbations estimated using the median inter-exacerbation 
times as time to the next exacerbation or death, whichever occurs first.
Note: Adapted from Long-term natural history of chronic obstructive pulmonary 
disease: severe exacerbations and mortality, Suissa S, Dell’Aniello S, ernst P, volume 
67, pages 957–963, copyright 2012 with permission from BMJ Publishing Group Ltd.4
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emergency-department visits, and 30-day readmissions within 
the period 2001–2012,48 highlighting considerable room for 
improvement and opportunities for reduction in the costs 
associated with admissions for COPD exacerbations. Patients 
who have been admitted to hospital for a severe exacerbation 
of COPD are at substantial risk for rehospitalization,19 with up 
to a quarter of patients readmitted for COPD exacerbations 
within 1 year following discharge.9,19 Strategies to reduce 
readmission rates are thus a priority in efforts to reduce the 
burden of severe COPD exacerbations.
What are the risk factors associated 
with severe COPD exacerbations?
The majority of COPD exacerbations, including severe 
exacerbations, are precipitated by respiratory tract infec-
tions, either viral or bacterial, or by environmental agents, 
eg, worsening air pollution.49 Numerous disease-related and 
demographic characteristics that modify patients’ risk of 
having an exacerbation have been identified.
Severity of airflow limitation is a key risk factor for 
exacerbation requiring hospitalization. In a retrospective 
study of ambulatory COPD patients from general practices, 
severity of forced expiratory volume in 1 second impairment 
was a significant predictor for increased risk of hospitaliza-
tions, as was the presence of significant comorbidities, such 
as diabetes or ischemic heart disease.50 The cross-sectional 
analysis of the PAC-COPD study found that patients with 
more severe respiratory symptoms, poorer QoL, worse lung 
function, and lower exercise capacity were at greater than 
threefold-higher risk of hospitalization for COPD than those 
with milder airflow limitation, with or without significant 
comorbidities (hazard ratio 3.28, P,0.001).51
A summary of variables that have been shown to modify 
the risk of severe exacerbations of COPD is shown in 
Table 1.4,6,18,19,26,50–78 These include lung function, symptoms 
(ie, severity of dyspnea), QoL, exacerbation history, disease 
history and treatment, age and sex, body-mass index, smok-
ing status, and comorbidities. Other influences on the risk of 
severe COPD exacerbations include the patient’s socioeco-
nomic background, education level, and marital status.
Exacerbations may occur regardless of the degree of 
functional impairment, although it is generally agreed that 
the frequency of exacerbations increases with decreasing lung 
function.1 A major audit of COPD treatment and outcomes 
in Europe was conducted by the ERS between 2010 and 
2011. This gathered a wealth of data (from more than 16,000 
Figure 2 emergency room visits and hospitalizations due to COPD exacerbations: Continuing to Confront COPD International Patient Survey.
Notes: Adapted with permission of Dove Medical Press Ltd, from Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease 
burden in 2012–2013, Landis SH, Muellerova H, Mannino DM, et al, volume 9, Copyright 2006; permission conveyed through Copyright Clearance Center, Inc.41 Calculated 
from response to the questions “In the past 12 months, did any of these episodes (worsening of your breathing problems) require an eR visit?” and “In the past 12 months, 
did any of these episodes (worsening of your breathing problems) require hospitalization?”
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admissions) profiling the demographic and disease charac-
teristics of patients admitted to hospital for exacerbations 
across the continent.10 The median age of patients admitted to 
hospital was 72 years.10 Many patients requiring hospitaliza-
tion due to an exacerbation had severe (Global Initiative for 
Chronic Obstructive Lung Disease [GOLD] grade 3, 39%) 
or very severe (GOLD grade 4, 22%) underlying COPD, 
but the proportion of patients with mild or moderate disease 
who experienced a severe exacerbation was not insignificant 
(GOLD grade 1, 15%; GOLD grade 2, 23%).10 Major comor-
bidities included other pulmonary diseases (21%), congestive 
heart failure (20%), and diabetes (20%).10
A systematic review of 37 COPD-treatment studies, 
with mean forced expiratory volume in 1 second percentage 
predicted lung function of mostly 35%–60%, estimated 
the annual frequency of severe exacerbations according to 
GOLD severity at 0.11 (GOLD grade 1, 95% CI 0.02–0.56), 
0.16 (GOLD grade 2, 95% CI 0.07–0.33), 0.22 (GOLD 
grade 3, 95% CI 0.2–0.23), and 0.28 (GOLD grade 4, 95% 
CI 0.14–0.63).65 In the ECLIPSE study, exacerbations were 
more frequent and severe with increased severity of disease: 
the proportion of patients hospitalized for COPD exacerba-
tions with GOLD grade 2–4 (moderate–very severe COPD) 
was 7%, 18%, and 33%, respectively.66
When we used the GOLD 2017 “ABCD” assessment 
tool (in which the lettering scale reflects symptom burden 
and risk of exacerbation)11 to analyze patients included 
in the UPLIFT® trial, a greater proportion of patients 
Table 1 Risk factors for severe exacerbations in COPD
Proposed risk factors for severe exacerbations by category
Lung function •	 Lower lung-function levels lead to higher rates of severe exacerbations and hospitalizations.50–53,65,66,70,74
Dyspnea •	 Severe dyspnea and recurring exacerbations are related to high health-care resource utilization, including frequent 
emergency visits and hospital admissions.6,54
•	 More than half (53%) of patients with MRC breathlessness scale scores 3–5 in the Global Hidden Depths of COPD survey 
had experienced an exacerbation requiring hospitalization in the previous year.57
BODe index •	 worsening (higher) BODe index score is associated with increased risk of exacerbation61 and hospital admission for an 
exacerbation.54,55
Health status •	 Poor health status predicts increased hospitalizations.6,26,62,64,66
•	 Impairment in health status and quality of life in COPD is a marker of risk for both frequent exacerbations and hospital 
admissions.77
Prior 
exacerbations, 
hospital visits, 
and hospital 
admissions
•	 Frequency and proximity of previous exacerbations predicts subsequent exacerbations and hospitalizations.4–6,52,53,66,70,74,78
•	 History of hospitalized exacerbations in the past 12 months is the strongest risk factor for future hospitalized 
exacerbation in eCLIPSe.6
•	 Severe exacerbation risk increases threefold after the second exacerbation requiring hospitalization and 24-fold after the 
tenth exacerbation.4
•	 Prior ER visits are a significant risk factor for exacerbation-related hospitalization.55
Age •	 Older age is a significant risk factor for hospitalization.62,70
•	 Older age is associated with shorter time to first readmission.69
Duration of 
COPD
•	 Patients with a longer history of COPD (.5 years) are approximately twice as likely to have frequent readmissions for 
COPD exacerbations.59
Comorbidities •	 Presence of significant comorbidities (eg, diabetes mellitus, cardiac insufficiency, ischemic heart disease) is associated with 
increase in risk, specifically for severe exacerbations requiring hospitalization.50
•	 Comorbidities associated with increased risk of hospitalization include cardiovascular disease, diabetes, asthma, psychiatric 
disorders (anxiety, depression), gastroesophageal reflux disease, and pulmonary hypertension.19,50,58,64,68,75
Blood-gas levels •	 Hypercapnia and poor arterial blood-oxygen saturation have been reported as being associated with hospitalization for a 
COPD exacerbation.55,67
BMI •	 Low BMI is associated with hospitalization and readmission for COPD exacerbation.67,72
Smoking status •	 evidence regarding impact of smoking status on risk of hospitalization is mixed,56 with some studies suggesting current 
smoking was associated with lower risk of hospitalization,52,70 others finding no association,50,67 and others indicating that 
smoking cessation reduces risk.63
Use of LTOT •	 Patients on LTOT are at increased risk of hospitalization for exacerbation.67
•	 Underprescription of LTOT increases the risk of hospitalization, due to severe exacerbations.52
Socioeconomic 
status
•	 Poorer health literacy increases the likelihood of COPD-related hospitalizations and emergency department visits.71
•	 Lowest education category and lowest income class are associated with a greater risk of hospitalization for 
exacerbations.60
•	 Unmarried patients are at greater risk of hospital readmission than those with spousal support; patients requiring social 
work intervention are likely to have an increased length of stay for hospitalized COPD exacerbations.76
Abbreviations: BMI, body-mass index; BODe, BMI, airway obstruction, dyspnea, and exercise capacity; eR, emergency room; LTOT, long-term oxygen therapy; MRC, 
Medical Research Council.
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(35%) in GOLD group D with higher symptom burden or 
exacerbation risk had experienced a severe exacerbation 
compared with patients with lower symptom burden or 
exacerbation risk (GOLD group A, 14%; group B, 22%; 
group C, 21%). Adjusted rates of severe COPD exacerba-
tions (per patient-year) were (mean [95% CI]): GOLD group 
A, 0.07 (0.05–0.09); group B, 0.13 (0.12–0.14); group C, 
0.13 (0.09–0.19); group D 0.28 (0.26–0.31) (Boehringer 
Ingelheim, data on file, 2017).
What are the recommended 
treatment strategies for severe 
COPD exacerbations?
Mortality statistics showing that the risk of death is highest in 
the first week following admission highlight the importance 
of prompt and effective intervention for patients admitted to 
hospital with severe exacerbations.4 Pharmacological treat-
ment options for severe exacerbations include bronchodilators 
(short-acting β-agonists with or without short-acting anticho-
linergics), corticosteroids (CSs) (eg, prednisone), and antibiot-
ics when the symptoms are suggestive of bacterial infection 
(eg, change in sputum characteristics).11,12 Full recommenda-
tions for the pharmacological treatment of exacerbations using 
bronchodilators can be found in published guidelines.11,12
Antibiotics
Based on available evidence that shows a reduced risk of 
short-term mortality and treatment failure, current GOLD 
recommendations are for antibiotic treatment in those patients 
whose exacerbation symptoms indicate likely bacterial infec-
tion, ie, increased sputum volume and purulence, as well as 
increased dyspnea.11 Antibiotics are also recommended for 
patients with exacerbations requiring mechanical ventilation, 
as this has been shown significantly to reduce mortality and 
the risk of secondary pneumonia.11
In this era of increasing antibiotic resistance, two key 
considerations are avoiding the use of unnecessary antibiotic 
treatment (ie, in patients who do not show an increase in 
purulent sputum)13 and ensuring that empiric treatment choices 
are selected based on knowledge of local bacteria-resistance 
patterns.11 Treatment selection might also consider how the 
microbiology may differ in patients with severe exacerbations 
versus patients with mild or moderate disease.79 The most 
common pathogens isolated from sputum and bronchoscopic 
samples are Haemophilus influenzae, Streptococcus pneumo-
niae, and Moraxella catarrhalis. However, in patients with 
more severe disease and/or exacerbations, Gram-negative 
pathogens, such as Pseudomonas aeruginosa, are common,79,80 
and may prove more challenging to treat in light of increasing 
resistance in some regions. The role of procalcitonin as 
a potential biomarker for optimizing antibiotic-treatment 
strategy in COPD exacerbations (especially those induced 
by bacterial infection) is also being investigated; however, 
as yet its role is unproven.81,82 Further studies are required 
to guide optimal antibiotic treatment, based on investigation 
of biomarkers to identify patients expected to benefit, and to 
establish the optimal duration of treatment.83
Corticosteroids
In the treatment of acute exacerbations of COPD, systemic 
CSs have been shown to reduce length of stay in hospital, 
provide earlier improvement in lung function and symp-
toms, and reduce the risk of treatment failure or relapse.84 
However, a US study has noted that critically ill patients 
admitted directly to an intensive care unit for the treat-
ment of severe exacerbations often receive higher-than-
recommended doses of CSs to combat inflammation in the 
lungs.85 A large cohort study of patients receiving low-dose 
(methylprednisolone #240 mg/day; ~6,000 patients) or high-
dose (methylprednisolone .240 mg/day; ~11,000 patients) 
CS treatment found that outcomes were in fact worse for 
patients treated with high doses of CSs.85 Higher doses were 
on average associated with longer hospital stays, longer time 
in the intensive care unit, and corresponding higher costs, as 
well as more steroid-related adverse events, compared with 
patients on lower doses of CSs. No significant difference was 
observed between patients treated with oral or intravenous 
CSs in terms of treatment failure, hospital readmissions, 
or length of hospitalization; however, intravenous therapy 
might increase the risk of adverse events. Overall, available 
evidence does not recommend one method of administration 
over the other.86
Optimal dosing regimens for oral CSs in patients with 
severe exacerbations have not been studied extensively; 
however, prolonged CS treatment is not recommended, in 
consideration of the adverse effects and lack of evidence 
for benefits of extended treatment. A recent meta-analysis 
suggested that a 5-day course of oral CSs was likely to be 
sufficient to treat patients hospitalized with a COPD exacer-
bation, and outcomes were not inferior to those with longer 
(10- to 14-day) courses.87
Oxygen therapy
During exacerbations, patients with COPD may become 
significantly hypoxic.88 Severe exacerbations disrupt the 
normal ventilation:perfusion ratio in the lungs, resulting in 
systemic hypoxemia, with poorly oxygenated blood returned 
to the left atrium.88 In a Spanish cohort of 2,487 patients 
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attending the emergency department due to acute exacerba-
tion of COPD, 50% had hypoxemia (arterial oxygen satura-
tion [SaO
2
] ,90%).89 Oxygen therapy is a key component in 
hospital treatment of patients with a severe exacerbation.11
There are marked variations in the response of individual 
patients to oxygen, and oxygen therapy may lead to hyper-
capnia and acidosis.90 Titrated controlled oxygen treatment 
for acute exacerbations has been associated with less acidosis, 
a lower requirement for assisted ventilation, and reduced 
mortality compared with high-flow oxygen.91,92 GOLD rec-
ommends titrating supplemental oxygen therapy to achieve 
a target saturation of 88%–92%.11 To achieve optimal oxy-
genation without carbon dioxide retention and/or worsening 
acidosis, blood gases should be monitored frequently.11
ventilatory support
Several studies have characterized the physiological changes 
that occur during or immediately after acute exacerbations, 
and have shown that lung hyperinflation and worsening 
airflow obstruction are the critical factors that determine 
the course of respiratory symptoms.93–95 Ventilatory support 
for the management of respiratory failure can be provided 
by either noninvasive or invasive methods, dependent upon 
patient criteria. Since its introduction in the 1980s, the use 
of noninvasive ventilation (NIV) has significantly increased, 
and has been associated with a reduction in mortality of 
approximately 40% and significantly reduced risk of treat-
ment failure, complications, and endotracheal intubation.96 
NIV is indicated in patients with respiratory acidosis (arte-
rial pH #7.35), severe dyspnea with clinical indicators of 
respiratory muscle fatigue, increased work of breathing, or 
both, and in patients on supplemental oxygen therapy who 
continue to experience persistent hypoxemia.11
It has been observed that patients who fail NIV and then 
transition to invasive mechanical ventilation have a higher 
rate of mortality compared with patients who start directly 
with invasive ventilation.97 Therefore, it is important to 
evaluate further the factors that predict early failure of NIV: 
to date, studies have identified severe acidosis, tachycardia, 
high APACHE II score, and severe hypoxemia as risk factors 
for NIV failure in patients with COPD exacerbations.12,97–99 
Further guidance on the use of ventilator support can be found 
in the GOLD report and ATS/ERS guidelines.11,12
Preventing severe COPD 
exacerbations
The profound impact of severe COPD exacerbations on 
patients’ well-being and the substantial economic burden 
associated with hospitalization highlights the importance of 
risk reduction as a key component of COPD management. 
Strategies to reduce the risk of subsequent exacerbations 
following hospitalization might be considered secondary pre-
vention in a similar way to the approach used in cardiology, 
using the index event as a critical point to review treatment 
and ensure optimal patient management to minimize the risk 
of future exacerbations.
Risk-factor modification
Smoking cessation
Smoking cessation has a substantial influence on the natural 
history of COPD, and is associated with a decrease in symp-
toms and improved health status. In a large observational 
cohort study of 23,971 US veterans, ex-smokers had a 
significantly reduced risk of COPD exacerbation compared 
with current smokers.100 The magnitude of reduction in risk 
was dependent on the duration of smoking cessation. Despite 
the evidence supporting the significant risk reductions that 
can be achieved through smoking cessation, a substantial 
proportion of patients continue to smoke. For example, the 
EU COPD audit data showed that approximately a third of 
patients admitted to hospital with severe exacerbations in 
Europe in 2010–2011 were current smokers.10 Reinforcing 
participation in smoking-cessation programs represents a sig-
nificant opportunity to reduce exacerbation risk by targeting 
a modifiable risk factor, particularly at hospital discharge, 
when patients may be particularly motivated to stop smoking 
to avoid experiencing another severe exacerbation.
vaccinations
Vaccination against influenza is a highly cost-effective inter-
vention for exacerbation reduction,101 and is recommended for 
all patients.11 In a retrospective cohort study of 1,323 patients 
with COPD, vaccination against seasonal influenza signifi-
cantly reduced hospitalization due to exacerbation ver-
sus patients who were not vaccinated.102 Protection may 
be enhanced by the addition of pneumococcal vaccine 
(although additive effects of influenza and pneumococcal 
vaccinations were only observed during the first year after 
vaccination).103
Pulmonary rehabilitation
Pulmonary rehabilitation may be offered after a severe exac-
erbation with the aim of restoring preexacerbation functional 
status, resuming physical activities in daily life, improving 
QoL, and reducing the risk of further exacerbations.11,101 The 
reported benefits of pulmonary rehabilitation on exacerba-
tions of COPD have been mixed, but the balance of evidence 
supports its use.104,105 In a meta-analysis of nine trials in 
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patients who had been hospitalized for an exacerbation, 
pulmonary rehabilitation significantly reduced future hospital 
admissions and mortality and improved QoL compared with 
usual community care.106 Pulmonary rehabilitation may 
reduce future exacerbations by targeting modifiable risk 
factors for readmission, such as physical inactivity, reduced 
exercise capacity, impaired physical function, central desen-
sitization to dyspnea, anxiety, and depression.73,104 Although 
the benefits of pulmonary rehabilitation are increasingly 
recognized and it is recommended in treatment guidelines 
for the prevention of acute exacerbations,11,13,107 availabil-
ity of pulmonary rehabilitation programs is often limited. 
For example, among hospitals surveyed in the EU COPD 
audit, only half offered a pulmonary rehabilitation program 
to patients discharged following a severe exacerbation 
(0%–90% across countries).10 Identifying barriers to avail-
ability and uptake of pulmonary rehabilitation would be a 
useful step toward improving prevention strategies.
Self-management intervention 
programs
Self-management intervention programs improve outcomes 
for many chronic diseases. A disease-management plan 
for COPD should include an action plan for exacerbation 
prevention, designed in partnership with the physician and 
the patient, and taking into account the patient’s experience 
of an acute (severe) exacerbation.101 Evidence for benefits 
of self-management plans for the prevention of COPD 
exacerbations is mixed. In one study, a self-management 
program for patients with COPD (comprising education 
on the disease, coughing and breathing techniques, energy 
conservation during daily activities, relaxation exercises, 
symptom prevention and control, an acute-exacerbation 
plan of action, and lifestyle advice, including nutrition and 
exercise) led to a 40% reduction in hospital admissions for 
exacerbations compared with usual care over 12 months.108 
Emergency visits were also reduced by 41% and unscheduled 
physician visits by 59%.108 Extended follow-up for 2 years 
demonstrated sustained benefits.62 A similar benefit was 
observed using a simplified disease-management program 
(a single education session, action plan for self-management 
of exacerbations, monthly follow-up calls).109 However, 
another randomized trial of patients with COPD found that 
a home education and management program did not result 
in a reduction in admissions for exacerbations, and in fact 
showed an unexpected increase in mortality.110 A Cochrane 
review suggested that overall, the balance of evidence sup-
ports the use of self-management programs to reduce the 
probability of respiratory-related hospitalizations,111 and the 
American College of Chest Physicians and Canadian Thoracic 
Society107 and ATS/ERS guidelines12 advocate their use.
Pharmacological strategies
Bronchodilators
Pharmacological agents currently available as maintenance 
treatment for COPD have varying efficacy for the prevention 
of COPD exacerbations. Long-term bronchodilator treat-
ment with a long-acting muscarinic antagonist (LAMA), 
long-acting β
2
-agonist (LABA), or a combination of both 
have been shown to reduce the risk of severe exacerbations 
significantly.25,112,113 Table 2 provides a summary of large-
scale randomized trials comparing the efficacy of inhaled 
maintenance COPD therapies in reducing exacerbation 
risk.114–134 The evidence base for LAMAs appears to be 
strongest, with a recent systematic review demonstrating 
that tiotropium is beneficial in reducing exacerbation risk 
versus placebo or other maintenance treatments, with longer 
time to first exacerbation event and fewer exacerbations 
(including hospitalizations) than either placebo or most 
active-comparator treatments.113 A fixed-dose LAMA–LABA 
combination of glycopyrronium and indacaterol successfully 
reduced moderate–severe exacerbations in patients of GOLD 
grade 3 or 4 compared with glycopyrronium alone, but this 
was not significant for severe exacerbations only.130 The 
FLAME study found that the combination of indacaterol–
glycopyrronium significantly prolonged time to first severe 
exacerbation compared with salmeterol–fluticasone, although 
the annual rate of severe exacerbations was not significantly 
different between the two treatment groups; however, it has to 
be noted that the FLAME study was not powered to analyze 
differences in severe exacerbations between groups.133
Despite the wealth of evidence to support tiotropium and 
other LAMAs in reducing the risk of severe exacerbations, 
data from the EU COPD audit indicate that they may be 
underutilized. Fewer than half of patients were on LAMA 
treatment prior to hospitalization, even though this patient 
population had been hospitalized once on average in the 
past year.10 Discharge following an exacerbation presents a 
pivotal opportunity to ensure that maintenance treatment is 
optimized, in line with goal-directed treatment guidelines 
to reduce the risk of disease progression, exacerbations, and 
mortality. Medication review at discharge, and at the same 
time also ensuring correct inhaler technique, represents a 
valuable opportunity for improvements in pharmacological 
approaches to reducing exacerbation risk. Adhering to 
COPD-treatment guideline recommendations is likely to 
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have a positive impact in terms of reducing the incidence 
of severe exacerbations. GOLD-adherent prescribing in 
COPD has been associated with significant reductions 
in proportions of patients with all-cause hospitalizations 
and emergency-department visits compared with nonad-
herent prescribing.135
ICS and ICS combinations
Due to the possible adverse events of pneumonia and fractures 
resulting from inhaled CS (ICS) treatment, current guidelines 
recommend ICS-combination therapy only in patients with 
severe airflow limitation at minimum and/or with frequent 
exacerbations that are not controlled adequately with long-
acting bronchodilators alone.11,13 The 3-year TORCH study 
found the ICS–LABA fluticasone–salmeterol combination 
therapy more effective than salmeterol alone in preventing 
moderate and severe exacerbations combined (rate ratio 
0.88), but not for severe exacerbations only.132 The overall 
lack of significant benefits of ICS–LABA treatment over 
LABA monotherapy was demonstrated in a systematic review 
of 18 randomized controlled trials, which failed to show a sig-
nificant decrease in the number of severe exacerbations.136
Phosphodiesterase-4 inhibitors
Phosphodiesterase-4 inhibitors do not have direct broncho-
dilator activity, but act as anti-inflammatory agents by inhib-
iting the breakdown of intracellular cyclic nucleotides.137 
Roflumilast is an oral phosphodiesterase-4 inhibitor, indi-
cated as a maintenance treatment for severe COPD associ-
ated with chronic bronchitis in adult patients with a history 
of frequent exacerbations (as add-on to bronchodilator 
treatment).138 The 1-year REACT study showed that in 
symptomatic patients with severe COPD and a history of 
exacerbations, roflumilast significantly reduced the risk of 
severe exacerbations in those already receiving an ICS–
LABA fixed combination, along with a LAMA (tiotropium in 
this study) as background treatment.139 A pooled analysis of 
two randomized trials enrolling patients with similar disease 
characteristics (but where approximately 50% continued 
with LABA therapy, and ICSs were not permitted) demon-
strated that roflumilast reduced the rate of moderate–severe 
exacerbations versus placebo, but had no significant impact 
on the rate of severe exacerbations.140 A post hoc analysis 
of the 52-week RE2SPOND trial showed that roflumilast 
reduced the rate of severe exacerbations in patients with 
frequent exacerbations (more than three exacerbations in 
the previous year) and/or history of hospitalization.141 The 
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patients with severe COPD, and evidence from these trials 
suggests that the benefits of roflumilast are demonstrated 
most consistently in patients with severe–very severe COPD 
associated with chronic bronchitis and a history of frequent 
exacerbations.142 Concerns have been raised regarding the 
safety profile of roflumilast, due to higher incidences of 
adverse events compared to other COPD medications;11 
however, a benefit–harm analysis of the use of roflumilast 
found a net benefit in patients with a high risk of severe 
exacerbations.143
Mucolytics
Mucolytic agents (specifically N-acetylcysteine [NAC]) 
may have a beneficial role in exacerbation reduction, 
with studies indicative of a reduction in exacerbation 
frequency.144,145 Although a Cochrane systematic review 
concluded that the small reduction in overall acute 
exacerbations achieved with mucolytics may have been 
overestimated,146 some studies suggest that higher doses of 
mucolytics (NAC 600 mg twice daily) may be particularly 
effective in patients with stable COPD,144 moderate–severe 
COPD,147 or at high risk of exacerbations.148 However, these 
studies were not specifically powered for the analysis of 
severe exacerbations. The current GOLD report concludes 
that regular use of mucolytic agents, such as NAC and 
carbocysteine, reduce the risk of exacerbation when used 
in appropriate patients.11
Antibiotic prophylaxis
Several studies suggest that the use of certain types of 
antibiotics may have a role in preventing exacerbations in 
certain groups of patients for whom the benefits outweigh 
the risks. Macrolides, which possess both antibacterial and 
anti-inflammatory effects, and fluoroquinolones are the 
classes of antibiotics studied most extensively for use in 
stable COPD, and prophylactic use over 1 year can reduce 
the rate of hospitalizations for COPD exacerbations com-
pared with placebo.149–153 While a meta-analysis of nine 
studies showed that macrolides are effective in reducing 
the overall rate of COPD exacerbations when administered 
for 6–12 months, the analysis was not able to demonstrate 
an effect on hospitalization rates, due to the low number of 
hospitalizations in the studies, which were not powered to 
detect such differences.151 Prophylactic antibiotic therapy 
should be applied cautiously, as the evidence remains 
limited, and further studies will be required to determine the 
optimal treatment regimen and duration with prophylactic 
use of antibiotics, and in what patients, to maintain a positive 
benefit–risk balance.150,151,154
vitamin D
It has been suggested that vitamin D supplements may 
help to prevent COPD exacerbations. The ViDiCO study 
demonstrated that vitamin D
3
 supplementation reduced the 
risk of moderate and severe exacerbations in patients with 
COPD;155 however, findings have been conflicting and the 
benefits may only be evident in patients with severe vitamin D 
deficiency.156 The PRECOVID study will be the first random-
ized trial to evaluate the effects of vitamin D supplementa-
tion on exacerbation prevention (primary outcome; rates of 
hospitalization will be a secondary outcome), and will recruit 
vitamin D-deficient patients who have recently experienced 
an exacerbation.157 The results of the study will be beneficial 
for establishing guidelines for vitamin D supplementation 
with regard to reducing exacerbation rates.
β-Blockers
β-blocker usage is low in patients with COPD and cardiovas-
cular comorbidities, as blockade of β-adrenergic receptors 
might induce bronchoconstriction and lead to bronchospasm 
and worsening of lung function. This is based largely on 
anecdotal evidence; however, review of the evidence base 
has indicated that cardioselective β-blockers (ie, those with 
greater affinity for β
1
- over β
2
-receptors) reduce overall 
mortality in patients with such conditions as coronary 
artery disease or MI and coexisting mild–moderate COPD, 
without producing clinically significant adverse respiratory 
effects, and should not be withheld.158–160 One observational 
cohort study (COPDGene®), which followed approximately 
3,500 patients for a median of 2.1 years, indicated that the 
use of β-blockers in COPD patients with cardiovascular 
comorbidities was associated with a significant reduction in 
exacerbation rates, including severe exacerbations. Effects 
were most pronounced in patients with severe COPD (GOLD 
grade 3 and 4 on home oxygen therapy).161 Randomized trials 
may be warranted to confirm whether this observation repre-
sents beneficial effects of β-blockers in COPD and explore 
the mechanisms underlying potential protective effects.
Readmissions
Patients who have been admitted to hospital for a severe exac-
erbation of COPD are at substantial risk of rehospitalization.18 
In the EU COPD audit, 35% of all patients admitted to 
hospital with COPD exacerbations were readmitted within 
90 days, and approximately three-quarters of readmissions 
were recorded as COPD-related.10 Readmission is a poor 
outcome for patients, and presents a significant strain on 
resources. In some cases, readmission is the result of a 
poor discharge, while in others it reflects the severity of the 
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underlying COPD or the presence of comorbidities.162 Despite 
best efforts, many readmissions may not be preventable. 
The US National COPD Readmissions Summit, as well as 
a recent systematic review, found that the evidence base to 
support specific interventions that would significantly reduce 
30-day readmission rates in patients hospitalized for COPD 
exacerbations was inadequate.163,164
Nevertheless, readmission rates are of increasing signifi-
cance to payers in both the US and the UK, where financial 
penalties have been imposed on hospitals with higher-than-
expected readmission rates, as part of an incentive to promote 
optimized, value-driven care packages for patients discharged 
following a COPD exacerbation. From a clinical perspective, 
it is important to monitor whether these approaches have 
unintended negative consequences, such as an increase in 
out-of-hospital mortality resulting from the disincentive to 
readmit patients who might genuinely benefit from further 
hospital treatment.163
Since a substantial proportion of readmissions are not 
due to COPD itself, but relate to comorbidities, effective 
management of these conditions and COPD is important in 
attempts to reduce readmission rates.56,162 Ensuring patients 
are on optimal maintenance treatment known to reduce 
exacerbation rates (as discussed earlier) at the time of dis-
charge is essential to reduce the risk of further exacerbations 
and readmission.
Improving overall disease-
management strategies
Several studies have revealed the frequency of clinical prac-
tices that are nonadherent to treatment guidelines, showing a 
disparity in treatment choices, overuse of CSs and antibiotics, 
and underuse of pulmonary rehabilitation.162–167 In a study 
conducted in the US, review of medical records indicated that 
patients with COPD received only 58% of the care recom-
mended by guidelines.168 A survey of respiratory specialists in 
Canada identified important care gaps regarding interventions 
to prevent future exacerbations, eg, suboptimal vaccinations, 
care plans, and patient education (39% of patients had never 
been taught how to recognize the signs and symptoms of an 
exacerbation). In the Continuing to Confront COPD Interna-
tional Physician Survey (12 countries), only 57% of primary-
care physicians and 58% of respiratory specialists provided 
treatment options concordant with the GOLD report for 
high-risk (GOLD grade 4) COPD.165 The EU COPD audit 
showed that COPD treatment received before admission for 
COPD exacerbation, inpatient treatment, use of mechanical 
ventilation, and discharge medications (including oxygen) 
varied widely across Europe.10 In addition, the organization 
of COPD care and hospital facilities was shown to vary 
considerably between countries.10
Adherence to therapy is an important factor in successfully 
preventing exacerbations. Poor adherence to COPD medi-
cation detrimentally affects long-term disease outcomes.169 
Among inhaled bronchodilators prescribed as maintenance 
therapy for COPD, adherence varies according to the type 
of medication, with higher rates of adherence observed with 
LAMAs (tiotropium in the study quoted) and relatively low 
adherence to ICSs or ICS–LABA combinations.170
Conclusion
Severe exacerbations are an important cause of morbidity 
and mortality, and have substantial economic consequences. 
A large number of potential risk factors are associated with 
severe exacerbations, many of which are easily identifiable 
and modifiable with careful patient management. Previous 
severe exacerbations and hospital readmission are significant 
risk factors for mortality; therefore, targeted interventions 
aimed at preventing or reducing severe exacerbations should 
be a priority for improving patients’ prognoses. Strategies to 
reduce hospital readmissions for COPD and related comor-
bidities are also required to reduce the economic burden 
associated with repeated hospitalizations.
Recent observational studies have reported lower rates 
of in-hospital mortality, reduced length of hospitalization, 
and fewer subsequent exacerbations over the past decade, 
reflecting improvements in care and greater awareness of 
the impact of COPD exacerbations. Nonetheless, effective 
prevention of severe exacerbations remains a significant 
unmet need in COPD. Both pharmacological and non-
pharmacological interventions have a role as part of a 
holistic package to minimize exacerbation risk. Smoking 
cessation is a key intervention, and improved access to/
uptake of pulmonary rehabilitation may be beneficial. Large 
randomized clinical trials have demonstrated the benefit of 
long-acting bronchodilators, such as LAMAs or LABAs, 
either as monotherapies or in combination, in reducing the 
risk of severe exacerbations in patients with COPD at all 
stages of severity. Overall, bronchodilators appear to be 
at least as effective as LABA–ICS therapy in preventing 
severe exacerbations of COPD. Antibiotics also have a 
role in selected patients, and influenza and pneumococcal 
vaccination can help prevent exacerbations. In conclusion, 
multiple opportunities to improve management of COPD 
and reduce risk of severe exacerbations are available, and 
should be considered in all patients with COPD, with 
particular attention paid to those who have already had a 
severe exacerbation.
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